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5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly-
(ADP-Ribose)Polymerases (PARPs) 
Michael D. Threadgill* 
Medicinal Chemistry, Department of Pharmacy & Pharmacology, University of Bath, Bath, UK 
Abstract: 5-Aminoisoquinolin-1-one (5-AIQ) is a water-soluble inhibitor of the poly(ADP-ribose)polymerases (PARPs), 
lacking isoform-selectivity. Although of only moderate potency in vitro against PARP-1, it is highly active in many assays in 
cells and in models in vivo, indicating excellent uptake. Optimisation of the several synthetic sequences to 5-AIQ has led to 
development of a short and efficient route from 1-chloroisoquinoline. It has been used widely as a biochemical and pharmac-
ological tool to study the effects of inhibition of the PARPs. It ameliorates the damage to cells and tissues following reperfus-
ion of ischaemic tissue, showing significant protective activity in a rodent model of haemorrhagic shock at the remarkably 
low dose of 30 g Kg-1. Protection is also seen in models of myocardial infarction, ischaemic kidney and liver disorders, 
stroke and organ transplantation. Inhibition of PARP-1 by 5-AIQ causes down-regulation of the activity of NF-B, which 
then down-regulates the expression of several gene products. Thus 5-AIQ has anti-inflammatory activity in vivo, through 
modulating the expression of cytokines and adhesion molecules. This indirect inhibition of expression is relevant in the activ-
ity of 5-AIQ in models of arthritis, Parkinson’s disease, multiple sclerosis, spinal cord injury, periodontitis and inflammatory 
conditions of the lung. Inhibition of expression of matrix metalloproteinases and other factors gives rise to anti-angiogenic 
activity and to remarkable anti-metastatic activity in a mouse model. Thus, although it has been overtaken by other PARP-
inhibiting drugs in the oncological clinic, 5-AIQ remains a valuable tool to study the roles of PARPs in health and in diverse 
diseases. 
 
Keywords: 5-AIQ, 5-Aminoisoquinolin-1-one, Cancer, Inflammation, Ischaemia-reperfusion injury, Metastasis, NF-B, 
Poly(ADP-ribose)polymerase. 
1. INTRODUCTION 
1.1. 5-AIQ 
5-Aminoisoquinolin-1-one (5-AIQ, 1, Figure 1) is a 
small-molecule inhibitor of the catalytic activity of several 
isoforms in the PARP superfamily. As its hydrochloride salt, 
it is highly water-soluble, unlike many inhibitors. This solub-
ility and good uptake into cells may contribute to its remark-
able potency in vivo. In this review, the discovery, chemistry 
and biological activities of this compound are explored, part-
icularly relating to its widespread use as a biochemical and 
biological tool. 
1.2. The PARPs 
The poly(ADP-ribose)polymerases (PARPs) comprise a 
superfamily of more than seventeen enzymes that catalyse 
the transfer of ADP-ribose units from NAD+ onto glutamate 
side-chains on acceptor proteins, biosynthesising polyanionic 
poly(ADP-ribose) polymers [1]. The archetypal PARP, 
PARP-1, was discovered over fifty years ago [2] and it was 
the sole known member until 1999, when Amé et al. repor-
ted a second PARP, PARP-2 [3]. PARP-1 is responsible for 
most of the poly(ADP-ribosyl)ation activity in the cell and 
has a major role in regulating the repair of damaged DNA. 
PARP-1 is a 116 KDa protein, comprising an N-terminal 
DNA-binding domain containing three zinc fingers [4], a 
central automodification domain containing a site for cleav-
age by caspase-3 [5] and a nuclear-localisation signal [6] and 
a C-terminal catalytic site, which binds the substrate NAD+. 
Two of the zinc fingers are responsible for sensing damage 
in the DNA, leading to PARP-1 being referred to as a 
“molecular nick sensor” [7]. PARP-2 is a smaller protein (62 
KDa), containing similar C-terminal NAD+-binding catalytic 
domain but with an N-terminal DNA-binding domain which 
lacks zinc-fingers but is highly basic in nature and which is 
responsible for protein-protein interactions. This PARP also 
has a role in identifying damaged sites in DNA. Interest-
ingly, one of the binding partners for PARP-2 is PARP-1 [8].    
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Figure 1. Structure of 5-aminoisoquinolin-1-one (1, 5-AIQ). 
2    Journal Name, 2014, Vol. 0, No. 0 Threadgill 
Whereas the NAD+-binding catalytic domains of PARP-1 
and PARP-2 have 69% similarity [3], there is an insertion of 
three contiguous amino-acids in PARP-2, possibly correlat-
ing with differences in the selection of acceptor proteins for 
the two isoforms. For example, whereas PARP-1 primarily 
poly(ADP-ribosyl)ates the linker histone H1, PARP-2 tends 
to modify core histones [9]. In addition to its role in opening 
the structure of chromatin around the site of DNA damage 
and recruitment of repair proteins, PARP-1 regulates the fun-
ction of NF-B in transcription [10,11], leading to implicat-
ion in inflammation [12], and in angiogenesis [13] and meta-
stasis [14,15] in cancer. PARP-1 is also over-activated in isc-
haemia-reperfusion injury, where the re-supply of molecular 
oxygen causes extensive DNA damage [16-21]. This over-
activation leads to rapid depletion and exhaustion of the cell-
ular supply of NAD+, part of its energy currency, leading to 
necrotic cell death. Whereas the roles of PARP-1 and PARP-
2 do overlap, particularly in response to DNA damage [22], 
some specific functions of PARP-2 have been identified [9], 
e.g. in spermatogenesis [23], thymopoeisis [24] and function 
of telomeres [25]. 
PARP-3 is a smaller protein, which, although its NAD+-
binding domain has some homology with those of PARP-1 
and PARP-2, appears to be a mono-ADP-ribosyl transferase 
[26]. Unlike PARP-1 and PARP-2, it is not activated by 
damage to DNA. It may have functions in regulating PARP-
1 [26], NuMA (at the mitotic spindle) and tankyrase-1 
(PARP-5a; at the telomere) [27]. Vaults are one of the small-
est organelles in mammalian cells [28]. Despite first being 
identified in 1986 [29], their precise role is still unclear, 
although they may be involved in trafficking of small molec-
ules or proteins or in multi-drug resistance. The major prot-
ein component is MVP, with smaller amounts of telomerase-
associated protein (TEP-1) and a large PARP, PARP-4 (193 
KDa). When isolated, PARP-4 (also known as vPARP) binds 
NAD+ and is catalytically active [30] but it is not known 
whether this activity is relevant to its function in the vault or 
if PARP-4 is merely a structural protein. 
The tankyrases (PARP-5a and PARP-5b) are a pair of 
closely related members of the PARP superfamily, with roles 
in regulating the lengths of telomeres, in the correct function 
of the mitotic spindle and in the wnt signalling pathway 
[31,32]. These two isoforms are almost mutually redundant, 
although some roles are currently thought to be fulfilled by 
tankyrase-1 alone. As most of the functions of the tankyrases 
are involved with proliferation of cells, there is considerable 
current interest in designing and developing selective and 
potent inhibitors for cancer therapy [33]. Other PARPs have 
received less attention as targets for drug design, although 
PARP-14 has recently been recognised as key to prolifera-
tion in multiple myeloma and in aggressive B-cell lymphoma 
[34-36]. 
1.3. Mechanism of poly(ADP-ribosyl)ation 
Scheme 1 shows the general chemical mechanism for the 
poly(ADP-ribosyl)ation reaction catalysed by PARPs. Subst-
rate NAD+ 2 binds into the catalytic site of the enzyme prin-
cipally through three strong hydrogen-bonds from the nicot-
inamide to Gly863 and Ser904 (human PARP-1 sequence num-
bering). Tyr907 also makes a -stack with the nicotinamide. 
This strong binding to the carboxamide in complex 3 stret-
ches and weakens the ribose-nicotinamide C‒N bond, facilit-
ating elimination of nicotinamide to form the intermediate 
oxonium species 4. Glu988 is located adjacent to the cation to 
provide stabilisation. The potent electrophile 4 is trapped by 
attack of an oxygen nucleophile on the -face; this nucleo-
phile is either the carboxylate of the side-chain of Glu in a 
target protein (for attachment of the first monomer) or a rib-
ose-OH (for subsequent ADP-ribosylation to build the poly-
mer). The approach of the nucleophile is always from the -
Scheme 1. General chemical mechanism for the poly(ADP-ribosyl)ation reaction catalyzed by PARPs, with amino-acids in the enzyme 
numbered as for PARP-1. General pharmacophore for compounds which inhibit PARPs. 
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face, generating the -glycosidic bonds in 5. The key feature 
of the non-covalent binding of NAD+ is the set of three 
hydrogen bonds to the nicotinamide and this is exploited in 
the design of most true inhibitors of PARP-1. 
This Scheme also shows the general pharmacophore for 
compounds which inhibit PARPs by binding as mimics of 
nicotinamide. The amide motif is essential for H-bonding 
with Ser and Gly at the active site. The carbocyclic ring 
should be aromatic, to make -stacking interactions with one 
or more Tyr residues. Regions where additional substituents 
are preferred or disallowed are shown; these regions vary 
between the PARP isoforms, facilitating the development of 
selective isoform-selective inhibitors. 
1.4. Inhibitors of PARPs 
The first selective inhibitor of PARP activity in lysed cells 
was 3-aminobenzamide (3-AB, 6, Figure 2), reported by 
Purnell and Whish in 1980 [37]. This compound contains the 
key pharmacophore for inhibition of PARPs, the aromatic 
carboxamide. Although of modest potency (IC50 = ca. 30 
M), its simplicity, selectivity for PARPs over other enz-
ymes using NAD+ and water-solubility led to it being the 
“gold standard” inhibitor for many years. Indeed, it is still 
used by some researchers. 
Several inhibitors of PARP-1 have entered clinical trial, 
as potentiators of conventional chemotherapy of cancer, as 
single-agent therapies in BRCA-mutant and triple-negative 
breast cancer and in ischaemia-reperfusion injury. Olaparib 7 
was first disclosed by Astra-Zeneca in 2008 [38] and pro-
ceeded to Phase-1 clinical trial, where it was well tolerated 
and showed promise in some patients with BRCA-mutated 
breast, ovarian and prostate cancer [39-43]. Phase-2 trials 
showed little beneficial effect in Ewing’s sarcoma [44] but 
good activity in BRCA-mutant ovarian carcinoma [45], 
leading to a successful Phase-3 trial in the latter disease and 
approval by the FDA in late 2014. However, some resistance 
to therapy with olaparib has recently been noted [46,47]. 
Rucaparib 8 was developed by Pfizer-Agouron from pion-
eering work at the University of Newcastle. It is showing 
useful activity in Phase-2 clinical trials, including potentiat-
ion of the therapeutic effects of the DNA-methylating drug 
temozolomide in melanoma [48]. In this drug, the secondary 
aliphatic amine in the side-chain allows for the formation of 
water-soluble phosphate salts. Veliparib 9 is the product of 
research at Abbott Laboratories. Phase-1 clinical trials were 
reported in 2011 and 2012, using the drug as a potentiator of 
the cytotoxicities of topotecan and of cyclophosphamide 
[49,50], and Phase-2 trials are ongoing. Tesaro Inc. very rec-
ently reported the discovery of niraparib 10 [51]. This drug 
successfully completed Phase 1 trial, showing some activity 
in BRCA-mutant ovarian and mammary carcinomas; it is 
now in Phase-3 trial [52]. INO-1001 11 was the subject of a 
clinical trial in 2009 in the context of addressing ischaemia-
reperfusion injury during treatment for myocardial infarction 
[53]. E-7449 shows interesting antiproliferative effects in 
acute myeloid leukaemia cells from patients [54]. The bind-
ing of the rationally designed BMN-673 to PARP-1 has been 
studied in detail [55,56]. A dose-escalation Phase-1 study 
using CEP-9722 14 to potentiate temozolomide achieved 
limited partial responses in melanoma [57], this compound is 
a water-soluble prodrug of CEP8983 15. GP-21016 / E-7016 
16 does not contain the usual NAD+-binding pharmacophore 
but is claimed to inhibit PARP-1 and potentiate the cytotoxic 
effects of temozolomide and of radiation in vitro and in vivo 
[58]. Iniparib 17 was initially claimed to be an inhibitor of 
PARP-1 in reports of pre-clinical studies but it failed in 
clinical trial. It was subsequently shown to be a non-specific 
thiol-reactive agent, not a specific inhibitor of PARP-1 [59]. 
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Figure 2. Structures of the first “gold-standard” selective inhibitor of PARP activity 3-AB (6) and the inhibitors which have entered clinical 
trial or which are of advanced interest (7-16). Iniparib 17 failed clinical trial and was later shown not to be a bona fide inhibitor of PARP-1.  
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2. 5-AIQ 
2.1. Discovery of 5-AIQ 
5-AIQ 1 was first synthesised by Wenkert et al. in 1964, 
as part of a chemical study on isoquinolinones, isocoumarins 
and related compounds, although the biological and pharma-
cological effects were not investigated [60]. The first report 
of the PARP-inhibitory activity of 1 came in 1991, when 
Suto et al. developed a series of simple 5-substituted iso-
quinolin-1-ones and 3,4-dihydroisoquinolin-1-ones [61,62], 
with the aim of inhibiting repair of DNA damaged by ionis-
ing radiation. The compounds were proposed as potential 
sensitisers of tumour cells to the cytotoxic effects of radio-
therapy of cancer. The rationale was that inhibition of the 
repair of DNA damaged by the X-radiation would allow the 
tumour cells to proceed in the cell cycle carrying the unrep-
aired damage and be arrested at checkpoints or fail in S-
phase, leading to apoptosis. 5-AIQ 1 was shown to have IC50 
= 240 nM against the activity of a semi-purified preparation 
of PARP-1 (the only PARP known at the time) but it was not 
evaluated for radiosensitisation. Thus 1 was shown to be ca. 
100-fold more potent than the standard at the time, 3-amino-
benzamide. This seminal paper also helped to define the 
pharmacophore for inhibition of PARP-1, setting out the re-
quirement for the secondary amide motif to be held coplanar 
with the benzene ring (Scheme 1) and identifying the need 
for a substituent at the 5-position of the isoquinolinones (but 
not at the 6- and 7-positions). Problems of very poor solubil-
ity were noted for the analogue (5-methyl-3,4-dihydroiso-
quinolin-1-one; PD 128763) taken forward to pre-clinical 
development [63,64] and most of the other isoquinolin-1-
ones. 
2.2. Chemistry of 5-AIQ 
2.2.1. Synthesis of 5-AIQ 
Scheme 2 shows the approaches that have been investig-
ated for the synthesis of 5-AIQ 1. Oxidation of 5-nitroiso-
quinoline 18 with hydrogen peroxide under acidic conditions 
gives the N-oxide 19 [60,61,65,66]. In the original synthesis 
of 1 by Wenkert et al. [60], a Polonovski rearrangement 
using boiling acetic anhydride was reported to provide 5-
nitroisoquinolin-1-one 20 in 74% yield. From here, reduction 
of the nitro group with hydrogen and palladium catalyst was 
straightforward. Work-up with hydrochloric acid was essen-
tial to convert 1 into its water-soluble hydrochloride salt to 
allow isolation and purification. This reduction has also been 
Scheme 2. Synthetic approaches to 5-AIQ 1. Reagents & conditions: i, H2O2, AcOH, reflux [60,61,65,66]; ii, (a) Ac2O, reflux, (b) aq. Na2CO3 
[60,61,65]; iii, H2, Pd/C, EtOH  [60,61,65] or Zn, NH4Cl, water, THF, EtOH [67] ; iv, Ph2O, 230C [68,69] or Bu3N, Ph2O, 230C [70,71] or 
tetraglyme, 280C [69]; v, Br2, (PhCO2)2, CCl4, h, reflux [72]; vi, Et4N+ -CN, MeCN [72]; vii, DiBAL-H, CH2Cl2, -78C [72]; viii, 
(MeO)2CHNMe2, reflux [65,67,73-75]; ix, (a) HCl, MeOH reflux, (b) aq. Na2CO3 [75]; x, SiO2, hexane, EtOAc [67,73,74]; xi, NH3, EtOH, 
autoclave [67] or NH3, EtOH, ambient temperature [74] or NH3, MeOCH2CH2OH, reflux [73]; xii, HNO3, H2SO4, 0C-20C [76-78] or 
KNO3, H2SO4 [79,80]; xiv, AcOH, 100C [78] or aq. HCl, reflux [81]; xiii, HgSO4, H2SO4, acetone, reflux [82]. 
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achieved with zinc under mildly acidic conditions [67]. This 
general route was also used by the Warner-Lambert Parke-
Davis group [61] but Watson et al. found the Polonovski re-
arrangement to be capricious and unreliable [65]. 
Eloy and Deryckere [68] devised a new approach to 5-
substituted isoquinolin-1-ones 23 through formation of 
ortho-substituted cinnamoyl azides 21, which were then 
thermolysed in diphenyl ether at 230C, triggering a Curtius 
rearrangement to the isocyanates 22 and electrophilic cyclis-
ation. This process is good when the substituent R is elec-
tron-donating and is satisfactory for electron-neutral groups. 
This group [68] subsequently published an enhancement of 
adding tributylamine as a high-boiling basic and nucleophilic 
catalyst. Berry et al. improved the method still further by 
using tetraglyme at 280C, facilitating isolation of the iso-
quinolinone products [69]. However, the rearrangement / 
cyclisation fails for R being electron-withdrawing (e.g. nitro) 
and the starting cinnamoyl azide is inaccessible for R = NH2, 
precluding access to 1 by this approach. 
Radical bromination at Ar-CH3 provided the bromomethyl 
derivative 25. Substitution with tetraethylammonium cyanide 
introduced the nitrile in 26, which was reduced selectively 
with DiBAL-H at low temperature to afford 20 in 23% yield 
[72]. This route was not adaptable to the synthesis of analo-
gues and was intolerant of other esters (e.g. Pri). 
 Watson et al. achieved condensation of the activated Ar-
Me in 2,6-dicyanotoluene 27 with dimethylformamide di-
methylacetal (DMFDMA) to give the enamine 28 [65]. 
Reaction with acid effected the hydration / cyclisation / hyd-
rolysis to 5-cyanoisoquinolin-1-one 29. Adapting this appr-
oach to the synthesis of 31, and hence 1, condensation of the 
Ar-CH3 of 24 with DMFDMA gave the corresponding 
enamine 30 [67,73-75]. From here, the enamine can be 
hydrolysed with aqueous acid, whereupon the intermediate 
enol cyclises to form the isocoumarin 31 [75]. Alternatively, 
this hydrolysis / cyclisation can be achieved by simply 
passing 30 through a column of silica gel [67,73,74]; pre-
sumably, the silica provides the necessary acid-catalysis. 
Replacement of the ring-oxygen with nitrogen (forming 5-
nitroisoquinolinone 20) has been effected with ethanolic 
ammonia at high temperature in an autoclave [67] and with 
ammonia in refluxing 2-methoxyethanol [73], avoiding the 
need for a pressure vessel. There is one curious report of the 
reaction with ammonia occurring at ambient temperature 
[74]. The sequence 24 → 30 → 31 → 20 → 1 proceeds in 
22% overall yield. 
The above sequence was the most efficient synthesis of 1 
for some years until Sunderland et al. disclosed a three-step 
process. Nitration of 1-chloroisoquinoline 32 occurs select-
ively at the 5-position [76-80], in contrast to nitrations of 2-
substituted isoquinolin-1-ones which tend to occur at the 4-
position [69]. Acetolysis of the 1-chloro of 33 and hydrolysis 
of the ester upon work-up forms 5-nitroisoquinolin-1-one 20, 
from which the target 1 can be obtained readily [77]. The 
hydrolysis of 33 to 20 can also be achieved in lower yield 
with aqueous hydrochloric acid [81]. This new sequence 32 
→ 33 → 20 → 1 proceeds in 54% overall yield [78]. 
Hg2+-catalysed 6-endo-dig cyclisation of the disubstituted 
alkyne 34a smoothly led to 5-nitro-3-phenylisocoumarin 35. 
However, the reaction could not be adapted to the synthesis  
Scheme 3. Reactivity of 5-AIQ 1. Reagents & conditions: i, coumarin-4-OCHMeCO2H, HATU, DMF [84]; ii, RCOCl, pyridine, acetone 
[85] or RCOCl, pyridine, 90C [78]; iii, Boc2O, Et3N, DMF [69]; iv, ArCMe2CH2C(OH)(CF3)CHO, Ti(OPri)4, xylene, 120C [86] or  
ArCMe2CH2C(OH)(CF3)CHO, Ti(OEt)4, xylene, 150C [87] or ArCMe2CH2C(OH)(CF3)CHO, AcOH, 20C [67]; v, BrCH2CO2Et, 
Pri2NEt, NaI, DMF, 80C [78]; vi, H2C=CH2CO2Me, NaH, THF [78]; vii, 43, Ph3P, DEAD [69]. 
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of the 3-unsubstituted analogue 31, as treatment with Hg2+ 
gave only the acetyl compound 36, the product of hydration 
of the terminal alkyne of 34b, via a 5-exo-dig first step [82]. 
2.2.2. Physical chemistry of 5-AIQ 
The hydrochloride salt of 5-AIQ 1 is a high-melting off-
white to buff solid, which is soluble to >5% in water but 
slightly less soluble in buffers. The free base is very poorly 
soluble in water and many other solvents. The calculated 
logP has been reported as -0.4 [83]. 
2.2.3. Chemical reactivity of 5-AIQ 
The structure of 1 contains three potentially nucleophilic 
sites (5-NH2, 1-C=O, 2-N) but no reactive electrophiles 
(Scheme 3). The 5-amino group is weakly nucleophilic and 
has been acylated with a carboxylic acid activated by 1-(bis-
(dimethylamino)methylene)-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate (HATU), forming 37 [84]. A 
range of amides 38 has also been formed using acyl chlor-
ides at ambient temperature in the presence of pyridine [85] 
or, more effectively, with acyl chlorides in hot pyridine [78]. 
t-Butoxycarbonyl protection has been introduced in 39 with 
di-But dicarbonate in the presence of a tertiary amine base. 
At one oxidation level lower, imines 40 have also been for-
med from 1 and aldehydes under forcing conditions with 
Lewis-acid catalysis (Ti(IV)) [86,87] or prolonged treatment 
in acetic acid at ambient temperature [67]. At one further 
oxidation level lower, 1 was alkylated at the 5-amine with 
ethyl bromoacetate under mildly basic conditions to form 41 
in low yield [78]. By contrast, use of the much stronger base 
sodium hydride deprotonated at 2-N and the resultant anion 
was alkylated by the conjugate electrophile methyl propen-
oate to give 42 with complete regioselectivity [78]. Protect-
ion of the 5-amine with Boc in 39 allowed Mitsunobu alkyl-
ation with 43 at 2-N to provide the putative (bio)reductively 
activated prodrug 44 [69]. 
Isotopomers of 1 have yet to be reported. 
2.3. Inhibition of isolated enzymes by 5-AIQ 
5-AIQ 1 was designed as an inhibitor of PARP-1, at a 
time when this was the only isoform known. The IC50 value 
for this inhibition has variously been reported as 240 nM 
(against semi-purified enzyme from calf thymus) [61], 300 
nM (against PARP activity in the lysate of nuclei from mur-
ine L929 cells) [65], 300 nM (against recombinant human 
PARP-1 using a radiochemical assay) [88], 1.17 M (using 
recombinant human PARP-1 in a scintillation proximity 
assay) [83], 940 nM (using recombinant human enzyme in a 
FlashPlate assay) [78], 250 nM [89] and 1.8 M (using re-
combinant human PARP-1 in the Trevigen assay) [90,91]. 
The diversity in values is probably due to the different assay 
conditions used, as the PARP reaction is sensitive to detailed 
changes in conditions. IC50 values for inhibition of the iso-
form PARP-2 are very similar, indicating no selectivity in 
binding. A value of IC50 = 1.84 M was reported for inhibit-
ion of recombinant mouse PARP-2 in a scintillation proxim-
ity assay) [83] and a similar study reported IC50 = 1.05 M, 
again using recombinant mouse PARP-2 [78]. No similar 
studies against the isoforms PARP-3 and PARP-4 have been 
carried out. However, a recent investigation by Paine et al. 
[93] revealed only modest inhibition of tankyrase-2 (PARP-
5b) at 1.0 M, again showing little selectivity between the 
isoforms of PARP. Qiu et al. confirmed this relatively weak 
binding to tankyrase-2 in determining IC50 = 10 M [89]. 
The selectivity of 1 for inhibition of PARPs, compared 
with mono-ADP-ribosyl transferases also using NAD+ as 
substrate, was shown by the higher IC50 for inhibition of the 
catalytic activity of diphtheria toxin (IC50 = 80 M) [65]. 
The compound is also reported to bind to and inhibit the 
PE24H catalytic domain of Pseudomonas aeruginosa exo-
toxin A, another bacterial mono(ADP-ribosyl)ating toxin, 
with IC50 = 23 M [93]. 
Weak off-target inhibition of matrix metalloproteinase-2 
(MMP-2) by 5-AIQ 1 and other agents designed to inhibit 
PARP-1 has been observed, with IC50 = 102 M for 1. Inhib-
itory potency against MMP-2 for the compounds broadly 
followed their potencies against PARP-1 [94]. However, 1 
has been reported not to inhibit the activity of human sirtuin-
1 [95]. 
Figure 3. Structures of 5-AIQ 1 bound into A: the catalytic domain of chicken PARP-1 (model from docking study) [1,96], B,C: the catal-
ytic domain of tankyrase-2 (PARP-5b) (crystal structures B: [90], C: [88]). 
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2.4. Binding of 5-AIQ to PARPs 
Structural studies showing the mode of binding of 5-AIQ 
1 to the target PARPs have revealed the designed hydrogen-
bonding interactions with the Ser / Gly motifs and -stacking 
with Tyr residues in the active site. Figure 3 illustrates the 
structures and binding. 
No crystal structures have yet been reported for the bind-
ing of 5-AIQ 1 into PARP-1 but a docking / molecular mod-
elling structure is in the public domain [1,96]. This structure, 
shown in Figure 3A, was prepared by replacing the ligand 
PD 128763 (5-methyl-3,4-dihydroisoquinolin-1-one) in the 
first crystal structure published for the NAD+-binding catal-
ytic domain of chicken PARP-1 [97] with the structure of 1, 
followed by molecular dynamics calculations and minimisat-
ion of energy. Ligand 1 binds as a strict analogue of the nic-
otinamide of NAD+. Hydrogen bonds are formed from the 
N–H of 1 to the carbonyl oxygen of Gly863 and from the car-
bonyl oxygen of 1 to the backbone NH of this Gly and to the 
side-chain OH of Ser904. The aromatic ring of Tyr907 forms a 
-stack with the ligand. The carboxylate of Glu988, involved 
in stabilising the intermediate oxonium ion, is within 5 Å of 
the 5-NH2. 
Two structures have been reported with 1 bound into con-
structs containing the catalytic domain of tankyrase-2 
(PARP-5b); these structures are broadly similar but differ in 
detail. Both structures [89,92] show the expected hydrogen 
bonds from the carbonyl of 1 to the side-chain OH of Ser1068 
and to the backbone N-H of Gly1032. The lactam N-H of 1 
forms a hydrogen bond with the backbone C=O of Gly1032, 
completing the classical hydrogen-bonding motif for binding 
of inhibitors to PARPs. -Stacking to the aromatic side-chain 
of Tyr1071 is also evident. Qiu et al. [89] claim an additional 
hydrogen bond from the 5-NH2 to a conserved water molec-
ule, whereas this water is absent from the structure reported 
by Paine et al. [92] and the side-chain carboxylate oxygen of 
Glu1138 is coplanar with 1 and located 4.6 Å from the 5-
amine nitrogen. 
2.5. Cellular and in vivo pharmacology of 5-AIQ 
2.5.1. PARP-1 and repair of damaged DNA 
Inhibitors of PARP-1 sensitise cells to killing by ionising 
radiation by slowing the rate of repair of the damage caused 
to DNA [98]. Although 5-AIQ 1 is a potent inhibitor of 
PARP-1, it showed little radiosensitising effect on V79 
Chinese hamster lung cells [62]. Conventional chemotherapy 
of cancer by drugs which cause single-strand breaks in DNA 
(e.g. alkylating agents, topoisomerase-2 poisons) is also 
potentiated by inhibition of PARP-1 [99-101] but there are 
no reports of evaluation of 1 in this context. 
2.5.2. 5-AIQ and ischaemia-reperfusion damage 
The role of PARP-1 in the cellular damage and death con-
sequent to reperfusion with molecular oxygen following isc-
haemia / hypoxia was identified as long ago as 1986 [102]. 
Briefly, this key involvement is as follows [102]: Occlusion 
of a blood vessel interrupts the supply of oxygenated blood 
to an organ. Restoration of the blood supply (spontaneously 
or through medical intervention) causes a rapid influx of 
molecular oxygen (an oxidising diradical) and generation of 
other reactive oxidising species, leading to extensive damage 
to DNA. PARP-1 is over-activated as part of the repair res-
ponse and quickly (<10 min) consumes the cytosolic reserve 
of NAD+. The drastic fall in the concentration of intracellular 
NAD+ leads to unavailability of this essential component of 
the energy-generating pathways, including glycolysis and 
mitochondrial respiration. The cell then runs out of energy, 
leading to necrotic death. PARP-1 is also involved in the in-
flammatory response to reperfusion, exacerbating the lethal 
effects on the cell. Pharmacological inhibition of PARP-1 
reduces or abolishes the cell death and organ damage con-
sequent to reperfusion injury [88,103,104]. 
Water-solubility and good bioavailability are key to suc-
cessful intervention with inhibitors of PARP-1 in reperfusion 
injury. The former is reflected in the remarkable potency of 
5-AIQ 1 in a rodent model of haemorrhagic shock [73]. 5-
AIQ inhibited the intracellular activity of PARP-1 in human 
cardiac myoblasts, in which oxidative damage had been 
caused by hydrogen peroxide, with IC50 = 10 M. Administ-
ration of 1 to rats, which had suffered haemorrhage, shortly 
before reperfusion mitigated the multiple organ failure seen 
in untreated animals in a dose-dependent manner, with sign-
ificant responses seen at the very low dose of 30 g Kg-1. 
Ischaemia / reperfusion injury is also a major component 
of damage in myocardial infarction. 5-AIQ 1 inhibited 
PARP-1 activity in H9c2 cardiac cells challenged with hyd-
rogen peroxide, with IC50 = 4.5 M, and dose-dependent sig-
nificant reduction in the size of the infarct was noted with 1 
in a rat model of myocardial infarction (occlusion of the des-
cending coronary artery, followed by removal of the occlus-
ion) [105]. Good activity was seen at doses down to 100 g 
Kg-1. Sodhi et al. reproduced this effect in isolated perfused 
rat hearts [106]. Significant attenuation of the size of the in-
farct and of release of the necrotic markers lactate dehydro-
genase and creatine kinase was achieved at a 5.0 M concen-
tration of 1, indicating good uptake into the tissue and cells. 
Interestingly, Park et al. suggest that at least part of the prot-
ective effect of 1 in H9c2 cells is due to up-regulation of the 
activities of superoxide dismutase and catalase and to activ-
ation of Akt and GSK-3 [107]. Balakumar and Singh used 
5-AIQ 1 (erroneously described as 5-aminoisoquinoline) as a 
tool to demonstrate that PARP-1 is involved in cardiac 
hypertrophy consequent to partial abdominal aortic constric-
tion but is not a component of the cardiac hypertrophy assoc-
iated with chronic swimming training in rats [108]. This re-
inforces the link between the protective action of 1 and isch-
aemia / reperfusion in the heart. 
5-AIQ 1 also protects against ischaemia / reperfusion 
damage in other organs. PARP-1 activity was inhibited in a 
concentration-dependent manner with IC50 = ca. 30 M by 1 
in primary proximal tubule cells from rat kidney after oxidat-
ive challenge with hydrogen peroxide, protecting the cells 
from necrotic death [109]. Moving to the situation in vivo, 1 
(300 g Kg-1) diminished the damaging effects of acute occ-
lusion of the arteries supplying the rat kidneys, followed by 
reperfusion, as shown biochemically and histologically. 
Curiously, 1 also protects the kidney against cisplatin-ind-
uced toxicity and restores function [110].  However, there is 
some dichotomy in the reports of the effects of inhibition of 
PARP-1 with 1 on ischaemia / reperfusion and oxidative 
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injury in the liver. 5-AIQ 1 was very effective at 3.0 mg Kg-1 
in ameliorating the damage to the microcirculation and fun-
ction in the livers of rats which had undergone haemorrhagic 
shock and resuscitation [111]. Khandoga et al. confirmed the 
protective effect on the microvasculature of the liver in the 
mouse but noted no overall effect on survival of the mice 
after occlusion and re-establishment of the hepatic blood 
supply [112]. 5-AIQ 1 was used as an inhibitor of PARP-1 to 
demonstrate that this enzyme is not involved to a major 
extent in the hepatotoxicity of acetaminophen / paracetamol 
[113]. Splanchnic artery occlusion shock in rats causes 
damage to the ileum and a lowering of mean arterial blood 
pressure. Both of these were diminished by treatment of the 
rats with 1 at 3.0 mg Kg-1 [114]. Interestingly, this splanch-
nic artery occlusion also caused an increase of the inflamm-
atory molecule ICAM-1, which was also diminished by 
treatment with 5-AIQ. 
A serious manifestation of ischaemia / reperfusion injury 
occurs in the transplantation of organs. Organs become hyp-
oxic when removed from the donor and are reperfused when 
installed in the recipient and it was proposed that treatment 
of the donor with erythropoietin and of the recipient with 5-
AIQ 1 was optimal for protection of the function of the 
organ [115]. A study by Szabó et al. showed that the PARP-
1 inhibitors PJ34 and 1 (wrongly named as 5-aminoisoquin-
oline) improved cardiac function in hearts transplanted bet-
ween rats, along with protecting against tissue damage dem-
onstrated by immunohistochemistry [116]. Reperfusion-ind-
uced graft coronary endothelial dysfunction was ameliorated. 
Inhibition of PARP-1 with these agents also decreased expr-
ession of P-selectin and ICAM-1. Similar effects of 1 were 
seen in rodent models of transplantation of kidneys 
[117,118]. Additionally, a protective effect of 1 has been 
demonstrated against acute rejection in cardiac transplantat-
ion, which was attributed to inhibition of the inflammatory 
response (vide infra) [119]. 
Módis et al. used the inhibition of PARP-1 by 5-AIQ 1 
human A549 cells in their detailed study [120], which concl-
uded that PARP-1 regulates bioenergetics both under normal 
conditions and in oxidative stress. This effect may be due to 
the effect of PARP-1 on the intracellular concentration of 
NAD+, rather than to regulation through poly(ADP-rib-
osyl)ation of a target protein. 
2.5.2. 5-AIQ and cytotoxicity 
The importance of over-activation of PARP-1 in the kill-
ing of human leukaemia HL60 cells by the antibiotic anti-
mycin A was demonstrated by Ogita et al. using 5-AIQ 1 
(wrongly named as 5-aminoisoquinoline) [121]. Antimycin 
A inhibits mitochondrial electron transport and induces the 
generation of reactive oxygen species and of nitric oxide. 
Reduction by 1 of the cytotoxicity caused by antimycin A, 
along with other data, indicated the role of PARP-1. 
By contrast, PARP-1 has been shown not to be involved 
in the repair of DNA damage and genotoxicity induced by 
boron neutron capture therapy (BNCT) [122]. This therapy 
relies on delivering the stable 10B isotope selectively to the 
tumour cells. The tumour is then irradiated with low-energy 
neutrons, which are captured by the 10B, leading to formation 
of a 7Li nucleus and an -particle. The latter causes lethal 
damage to DNA. 5-AIQ 1 and other PARP-1 inhibitors did 
not diminish this damage in V79 Chinese hamster cells, 
which is consistent with the formation of double-strand 
breaks whereof PARP-1 is not involved in repair. 
2.5.3. 5-AIQ and inflammation 
As noted above, PARP-1 is involved in inflammatory pro-
cesses; this role has recently been reviewed [12]. Potent anti-
inflammatory activity has been shown for 5-AIQ 1 in a wide 
variety of models of inflammation with different triggers in 
different tissues and organs. 
Cuzzocrea et al. proposed the use of 5-AIQ 1 in the treat-
ment of inflammatory bowel disease, on the basis of its ben-
eficial effect in mice with colitis induced by dinitrobenzene-
sulfonic acid [123]. In these mice, 1 (3.0 mg Kg-1) reduced 
the incidence and severity of diarrhoea and loss of weight. 
Infiltration by neutrophils, myeloperoxidase activity and up-
regulation of ICAM-1 were also reduced markedly by this 
dose. 
The same group also noted an anti-inflammatory effect of 
1 in a rat model of periodontitis [124]. Periodontitis was 
induced with a ligature around a tooth, leading to increased 
infiltration by neutrophils in the inflamed tissue, along with 
increased local myeloperoxidase activity and resorption of 
bone matrix. 5-AIQ 1 (5.0 mg Kg-1) significantly reduced 
these and other parameters of inflammation. 
In the kidney, 5-AIQ 1 (3.0 mg Kg-1) markedly reduced 
thrombotic lesions and glomerulosclerosis in vivo in mice 
with nephrotoxic serum-induced immune-mediated nephritis 
[125]. The kidneys from 5-AIQ-treated animals showed less 
poly(ADP-ribose), showing that the drug addressed the 
target PARP-1, and lower expression of TNF-. Similarly, in 
a model of accelerated lupus nephritis, treatment with 1 de-
pressed the concentration of blood urea nitrogen (BUN) and 
histopathological examination showed lower lymphocyte in-
filtration, cellular proliferation and necrotic cell death. This 
led to a suggestion that 1 could act to block the development 
of spontaneous lupus nephritis through inhibiting PARP-1. 
The beneficial effects of inhibition of PARP-1 with 5-AIQ 
1 on inflammation in the lung have been extensively studied. 
Idiopathic pulmonary fibrosis is an inflammatory disease in 
humans in which there are excessive deposits of extracellular 
matrix in the lung. It does not respond well to current treat-
ments with corticosteroids and cytotoxins. Genovese et al. 
developed a mouse model of the condition, in which the fib-
rosis is induced by the antineoplastic drug bleomycin [126]. 
Treatment with 5-AIQ 1 ameliorated the fibrosis and inflam-
mation at a dose of 3.0 mg Kg-1. Reductions in PARP activ-
ity and in formation of nitrotyrosine were observed, along 
with benefits in lower mortality and in maintenance of body 
weight. Thus 1 is confirmed as an effective inhibitor of 
PARP-1 in lung tissue in this model. Kawasaki et al. 
reproduced these effects in a similar model of bleomycin-
induced pulmonary fibrosis in the mouse [127], comparing 1 
with the known antifibrotic drugs valsartan and erythro-
mycin. In an earlier study, acute inflammatory lung injury 
was induced with zymosan-activated plasma in BALBc mice 
[128]. Inhibition of up-regulation of ICAM-1 and P-selectin 
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was observed with administration of 1 at 3.0 mg Kg-1, dem-
onstrating an anti-inflammatory effect in vivo, as well as a 
diminution of lung injury. These results were paralleled in 
vitro in human endothelial cells challenged with oxidative 
stress or a pro-inflammatory cytokines (TNF-), with signif-
icant dose-dependent reduction in release of ICAM-1 and of 
P-selectin from as low as 3.0 M of 1. In a model of chronic 
asthma in guinea pig, where the animals were sensitised with 
ovalbumin, 5-AIQ 1 was protective at the low dose of 500 
g Kg-1 [129]. Cough and dyspnoea were significantly red-
uced, along with PARP-1 activity in the lung and markers of 
inflammatory lung damage (e.g. TNF-). Very recently, 
Ahmad et al. reported a study in which inflammation was 
induced in mouse lung with carrageenan [130]. Treatment 
with 5-AIQ 1 (1.5 mg Kg-1) diminished the over-expression 
of a wide range of molecules associated with inflammation, 
including COX-2, STAT-3, NF-B, p65 and PARP-1 itself 
and relieved the suppression of IB- and IL-4. The authors 
concluded that 1 is a potent anti-inflammatory agent. 
2.5.4. 5-AIQ protects against neuronal disfunction 
Inflammatory processes subsequent to the injury play an 
important role in neuronal death and malfunction after spinal 
cord injury. As noted above, 5-AIQ 1 has strong anti-inflam-
matory effects, owing to its inhibition of PARP-1 activity 
and its good uptake into cells. Genovese et al. explored the 
extension of the applications of this agent into treatment of 
spinal cord injury [131]. In a mouse model involving temp-
orary compression of the spinal cord, 5-AIQ 1 (3.0 mg Kg-1) 
inhibited the formation of poly(ADP-ribose) and reduced in-
flammation and spinal cord injury (shown histologically) and 
diminished apoptosis. A reduction of the binding of NF-B 
to DNA was also observed, along with preservation of IB, 
re-inforcing the concept that PARP-1 may regulate the 
function of NF-B. In a truly functional assay, the motor 
score of the hind limbs of the animals also recovered well 
after treatment with 1. This study was backed up later by an 
observation that inhibition of PARP-1 with 1 modulates cell-
ular autophagy in spinal cord trauma [132]. 
Ischaemic stroke results from restricted flow of oxygen-
ated blood in one or more arteries supplying the brain. Cells 
die in two phases, initially from deficiency of oxygen and, 
after restoration of the supply of blood, from excitotoxicity, 
inflammation and oxidative stress [133,134]. PARP-1 has 
been identified as a major player in the cell death consequent 
to reperfusion in stroke, inter alia through its regulation of 
NF-B. PARP-1 can also cause neuronal cell death through 
parthanatos [135], a caspase-independent form of apoptosis, 
as over-activated PARP-1 causes translocation of apoptosis-
inducing factor (AIF) to the nucleus [136], where it triggers 
condensation of chromatin and fragmentation into large 
pieces [137]. Microglial activation can take hours to days to 
develop after a stroke [138], giving a time-window for ther-
apy. However, Yennari et al. point out that the immune res-
ponse can have beneficial effects as well as deleterious out-
comes [139]; this is of relevance to inhibition of PARP-1, as 
this enzyme is involved in angiogenesis (vide infra) and 
inhibition of vascular remodelling may be undesirable. In 
this context, 5-AIQ 1 (3.0 mg Kg-1) has been shown to dim-
inish significantly the oxidative activity of infiltrating neut-
rophils in a rat model of chronic ischaemic stroke but not in 
an acute model [139]. 
Other neurological disorders have also responded to treat-
ment with 5-AIQ 1. Parkinson’s disease is characterised by 
degeneration of dopaminergic neurons of the substantia nigra 
in the brain. Dopaminochrome, an oxidised derivative of 
dopamine, is cytotoxic to these neurons, causing apoptosis. 
This apoptosis is mediated through translocation of apopt-
osis-inducing factor (AIF) to the nucleus, a process triggered 
by PARP-1 activity [140]. 5-AIQ 1 protects against this 
apoptosis in the murine mesencephalic cell line MN9D; the 
lowest concentration used was 50 M, which may have been 
unnecessarily high. Farez et al. noted that the activity of 
PARP-1 is higher in patients in the progressive phase of mul-
tiple sclerosis (secondary progressive multiple sclerosis, 
SPMS) [141]. Higher serum concentrations of 15-hydroxy-
cholestene are also found in these patients and in mice with 
secondary progressive experimental autoimmune encephalo-
myelitis (EAE). 5-AIQ 1 (3.0 mg Kg-1) inhibited the clinical 
signs of EAE. A detailed study confirmed toll-like receptor-2 
(TLR2) and PARP-1 as a pathway in the pathology of the 
disease. One may speculate that this pathway could be a 
useful point of therapeutic intervention in this devastating 
progressive disease. 
2.5.5. 5-AIQ and arthritis 
Interesting anti-inflammatory activity is also seen for 5-
AIQ 1 in model of arthritis. Ahmad et al. induced arthritis in 
mice using Complete Freund’s Adjuvant containing heat-
killed M. tuberculosis. Significant relief of the symptoms of 
the arthritis (e.g. oedema, erythema, joint function) were 
seen after treatment with 1 (1.5 mg Kg-1) [142]. At the cell-
ular level, 1 decreased the number of pro-inflammatory sub-
sets of T-cells, while increasing the number of Treg cells; 
reduction of expression of NF-B and other inflammatory 
mediators was observed, along with up-regulation of IB- 
and mRNA for anti-inflammatory mediators. This detailed 
study followed earlier work in collagen-induced arthritis by 
Gonzalez-Rey et al., in which 1 (1.5 mg Kg-1 and 3.0 mg 
Kg-1) strongly relieved the damage to tissue and bone caused 
by the arthritis [143]. Down-regulation of pro-inflammatory 
cytokines was observed, along with stimulation of IL-10, an 
anti-inflammatory cytokine. The authors concluded that 
PARP-1 could be an important target protein for the design 
of new drugs for the treatment of rheumatoid arthritis. 
2.5.6. 5-AIQ and cancer 
Many of the above observations strongly suggest that 
PARP-1, in addition to its role in regulating the repair of 
damaged DNA, regulates the expression of a number of 
genes and that this latter regulation can be modulated effect-
ively by 5-AIQ 1 in whole cells and tissues. In direct studies 
on the modulation of expression of genes by 1, it has been 
shown that, in T cells, the expression of transforming growth 
factor- (TGF-) receptor sub-type I is up-regulated by this 
agent [144]. TGF- receptor-II is also regulated by PARP-1 
but by protein-protein interaction rather than through enzym-
atic activity. Cai et al. found that 5-AIQ 1 inhibits the exp-
ression of PARP-1 itself in CT26 colon carcinoma cells, 
although 1 was used at the very high concentration of 100 
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M which may possibly have led to inhibition of enzymes 
other than PARP-1 [145]. The authors proposed that this 
effect on expression of PARP-1 was due to inhibition of 
PARP-1 activity, leading to down-regulation of the activity 
of NF-B. Following on from this initial study, the same 
group confirmed the effect on the expression of PARP-1 but 
also observed that the expression of vascular endothelial 
growth factor-C (VEGF-C) was down-regulated by 1, though 
inhibition of PARP-1 and down-regulation of NF-B [146]. 
VEGF-C is involved in angiogenesis, so the authors propo-
sed that PARP-1 may regulate angiogenesis and inhibition 
thereof with 1 may inhibit this process. Rajesh et al. confir-
med that 1 does inhibit the processes of angiogenesis, in 
common with other inhibitors of PARP-1 [147]. The prolif-
eration of HUVEC human umbilical cells triggered by 
VEGF and by fibroblast growth factor (FGF) was inhibited 
significantly by 1 at 600 nM concentration. Inhibition of pro-
liferation was also seen in the ex vivo rat aortic ring model at 
1.2 M concentration, a lower concentration than those re-
quired for other inhibitors of PARP-1.  
Having established that primary samples of human colon 
carcinoma, especially metastatic cancer, had higher levels of 
poly(ADP-ribosyl)ation than adjacent normal colon and that 
these higher levels correlated with higher expression of P-
selectin and ICAM-1, Wang and Hao noted that inhibition of 
PARP-1 with 5-AIQ 1 down-regulated the expression of 
these adhesion molecules in the HT29 human colon carcin-
oma line and diminished their ability to adhere to HUVEC 
cells [148,149]. The authors suggested that 1 may have anti-
metastatic properties. Similar results were seen in CT26 
murine colon carcinoma cells, with treatment with 1 reduc-
ing the levels of expression of NF-B, integrin-1, MMP-2 
and MMP-9. Interestingly, the expression of PARP-1 was 
also lower. The protease activities of the MMPs were also 
diminished, as shown by zymography [150], although 1 does 
have a weak direct inhibitory effect on MMP-2 [94]. Cells 
treated with 1 migrated significantly less through Matrigel 
and were less invasive in vitro, leading to the conclusion that 
1 exerts its anti-migration effect through inhibition of PARP-
1, which then down-regulates NF-B, which, in turn, down-
regulates the expression of metastasis-related genes. The 
Chongqing group then confirmed the strong anti-metastatic 
effect of 1 (3.0 mg Kg-1) in vivo in abolishing the metastasis 
into the liver of CT26 cells implanted in the spleen [15]. 
Some reduction in the volume of the primary tumour in the 
spleen was also observed. Selective killing of cell lines 
carrying mutated BRCA1 or BRCA2 by inhibitors of PARP-
1 was first reported in 2005 [151,152] and olaparib 7 is lic-
ensed for treatment of BRCA-mutant tumours as a single 
agent [47]. One may speculate about the involvement of 
BRCA in the apparent anti-tumour activity of 1 but the 
BRCA-status of the CT26 line has not been reported. Finally 
in the context of cancer, it has been shown that inhibition of 
the mono(ADP-ribosyl)transferase ART1 acts synergistically 
with inhibition of PARP-1 with 1 to promote apoptosis in 
CT26 cells treated with cis-platin; down-regulation of 
NF-B and of COX-2 was observed [153]. ART1 is inhib-
ited weakly by the weak PARP-1 inhibitor 3-AB 6 [154]. 
Unfortunately, the direct inhibitory effect of 5-AIQ 1 on 
ART1 has not been reported but it is known not to affect the 
expression of the ART1 protein [130]. siRNA silencing of 
ART1 has an anti-proliferative effect in CT26 cells [155] and 
one might question whether the observed anti-tumour effect 
of 1 may be due to simultaneous inhibition of ART1 and 
PARP-1. 
2.5.7. 5-AIQ and fertility 
The effects of 5-AIQ 1 on fertility and on development of 
the foetus are mixed. Treatment of female mice with 1 stim-
ulates the production of mature oocytes, in a dose-dependent 
manner (1.2 mg Kg-1 and 3.0 mg Kg-1) [156]. Qian et al. also 
report that the number of foetuses produced by female mice 
treated with 1 was higher than for control mice and that these 
foetuses showed no signs of abnormalities. These effects 
were absent in mice in which the gene encoding for PARP-1 
had been knocked out, confirming that 1 was acting via in-
hibition of this enzyme. By contrast, Osada et al. reported 
that inhibition of PARP-1 with PJ34 or with 1 caused devel-
opmental arrest at the pronuclear envelope breakdown stage 
of fertilisation, citing effects at the spindle bundles and def-
ective polymerisation of tubulins [157]. One may speculate 
whether these effects are due to inhibition of PARP-1 or to 
the weak collateral inhibition of the tankyrases (PARP-5a 
and PARP-5b) by these compounds [31,92,158], as the tank-
yrases are involved in the correct functioning of the mitotic 
spindle [159]. PJ34 and 1 were observed to cause changes in 
the methylation of histone H3 (increased at Lys4 and decrea-
sed at Lys9) and hypomethylation of DNA in the pro-embryo 
soon after fertilisation [160]. It was suggested that inhibition 
of PARP-1 may be a target in contraception [159] but the 
dichotomy of observed effects would have to be resolved 
before this approach is viable. 
5-AIQ 1 appears to be devoid of genotoxicity in vitro and 
in vivo, according to a study by Vinod et al. [161]. 
2.6. Substituted analogues of 5-AIQ 
2.6.1. 5-NH2-Substituted analogues of 5-AIQ 
Several sets of analogues of 5-AIQ substituted at the exocyc-
lic 5-NH2 have been reported to have been prepared and 
evaluated for different applications. Compound 37 (Schemes 
2 and 4) was evaluated as a member of a series of 4-substit-
uted coumarins by Rambabu et al., who found it to be a very 
weak inhibitor of cyclooxygenases [84]. The 5-acylamido-
isoquinolin-1-ones 38 (R = Me, cyclopropyl, Ar, (substit-
uted)Bn, BnO) were used as intermediates by Chen et al. en 
route to the corresponding 5-acylaminoisoquinoline-1,3,4-
triones 45, which were potent inhibitors of caspase-3 (IC50 = 
40 to 356 nM) [85]. Good selectivity was seen vs. other prot-
eases but the compounds were effectively non-selective bet-
ween the caspase isoforms [85]. Sunderland et al. found that 
similar compounds 38 (R = Ar, adamantyl, But, cHex, thio-
phene) were inhibitors of PARP-1 and PARP-2, with the 
benzamide 38 (R = Ph) being 9.3-fold selective for inhibition 
of PARP-2 [78]. In a comparative study, this benzamide was 
more selective than the corresponding ester 46, which had 
earlier been claimed to be highly selective [162] but which is 
probably hydrolytically unstable in aqueous solution. These 
researchers also hydrolysed the ester 41 to the carboxylic 
acid 47, which showed moderate potency against both iso-
forms [78]. The group of Rehwinkel and Krolikiewicz 
[67,86,87] used an imine linkage to join a variety of pharma-
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cophores onto the isoquinolin-1-one core in 40, aiming to 
prepare anti-inflammatory agents. An interesting synthesis of 
38 (R = Et, Bn) by photolytic Polonovski rearrangement of 
the precursor N-oxides 48 was disclosed [163], as part of an 
attempt to access 4-methoxyindole. Incorporation of the 5-N 
in a 1,2,4-triazole (in 49) led to inhibitors of Gly transporter-
1 [164]. 
2.6.2. 2-N-Substituted analogues of 5-AIQ 
Hydrolysis of the ester function of the 2-N-substituted 5-
aminoisoquinolin-1-one 42 provided the acid 50 (Scheme 4) 
Remarkably for a compound which does not fit the general 
pharmacophore for inhibition of PARPs in that it lacks the 
lactam N-H (Scheme 1), 50 is almost as potent as is the par-
ent 1 against PARP-1 (IC50 = 550 nM) and has good activity 
for inhibition of PARP-2 [78]. 2-N-methyl-5-AIQ 51 has 
been accessed synthetically in several ways. Horning et al. 
reduced the 5-nitroisoquinolin-1-one 52 to 51 with hydrazine 
and Raney nickel [165], whereas Henry et al. effected the 
same conversion by catalytic hydrogenation [166]. Somei et 
al. used the reduction of 52 to 51 as an example in their dev-
elopment of the use of TiCl3 as a reagent for the selective 
high-yielding reduction of aromatic nitro compounds [167]. 
Attempting to adapt this procedure to selective reduction of 
the nitro group of the quaternary isoquinolinium salt 53, 
Knefeli et al. unexpectedly achieved the complex oxidation / 
reduction sequence leading to the isoquinolinone 51 [168]. 
By contrast, Möhrle and Biegholdt selectively oxidised the 
tetrahydroisoquinoline 54 to a mixture of the 3,4-dihydroiso-
quinolin-1one 55 and the isoquinolin-1-one 51; surprisingly, 
the arylamine was untouched by the oxidising Hg(II) com-
plex [169]. The presence of the 5-NH2 in 56 abolishes the 5-
HT3-antagonist activity of the 2-N-imidazolylmethylisoquin-
olin-1-one unit, whereas primary amines are tolerated well at 
the 6-, 7- or 8-positions [170]. 
2.6.3. 3-Substituted analogues of 5-AIQ 
Scheme 5 shows the C-substituted analogues of 5-AIQ 
and the associated chemistry. By far the largest group of C-
substituted derivatives known are the 3-alkyl and 3-aryl-5-
aminoisoquinolin-1-ones 59, owing to their potent biological 
activity. The 3-substituted-5-nitroisocoumarins 57 have been 
prepared by Hg2+-catalysed ring-closure of methyl 2-aryleth-
ynyl-3-nitrobenzoate [82], tandem Castro-Stevens – ring-
closure of 2-halo-3-nitrobenzoic acid and arylethynes [82] or 
tandem Hurtley coupling – retro-aldol – ring-closure [171] 
processes. The oxygen is displaced with ammonia under for-
cing conditions, giving 58, in which the nitro group can be 
reduced to afford the 3-substituted-5-aminoisoquinolinones 
59 [92,172]. Paine et al. devised a more efficient route to 
these important targets, assembling the 3-aryl-1-methoxy-5-
nitroisoquinolines 60 by Suzuki couplings of arylboronic 
acids with 3-bromo-1-methoxy-5-nitroisoquinoline [92]. De-
methylation unmasked the lactam (giving 58 (R = Ar). Alter-
Scheme 4. Structures of reported N-substituted analogues of 5-AIQ and associated chemistry. Reagents: i, K2Cr2O7 [85]; ii, h [162]; iii, 
N2H4.H2O, Raney Ni [165]; iv, H2, Pd/C [166]; v, TiCl3 [167,168]; vi, Hg2+ / EDTA [169]. 
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natively, 60 were reduced to the 5-aminoisoquinolines 61, 
which were demethylated to give 59 (R = Ar) [92]. 
The 3-alkyl- and 3-aryl analogues 59 of 5-AIQ were 
developed and optimised as part of a major study towards 
potent and selective inhibitors of the tankyrases (PARP-5a 
and PARP-5b) [92]. Particularly potent were compounds 
carrying para-substituted phenyl at the 3-position, with 59 
(R = 4-MePh) having IC50 = 39 nM vs. tankyrase-1 and IC50 
= 34 nM vs. tankyrase-2. Isoform-selectivity was moderate-
to-good for the 3-aryl compounds, with 59 (R = 4-MePh) 
showing IC50 = 880 nM vs. PARP-1. Interestingly, several of 
these 3-aryl-5-AIQs were markedly cytotoxic towards tum-
our cell lines, with IC50 values in the low M range. 
2.6.4. 4-Substituted analogues of 5-AIQ 
4-Methyl and 4-aryl derivatives of 5-AIQ have been app-
roached by two distinct synthetic routes (Scheme 5). Dhami 
et al. carried out Pd-catalysed C=C bond migration and intra-
molecular Heck reaction of the N-allyl- and N-cinnamyl-2-
iodobenzamides 62 [90] Isomeric mixtures of 63 and 64 
were formed, with the ratios depending on the rate of heating 
to 150C, contributing to the conclusion that -allyl-Pd spec-
ies were involved in the cyclisation. Reduction gave 5-
amino-4-methylisoquinolin-1-one and 5-amino-4-benzyliso-
quinolin-1-one 65. 
Sunderland et al. used intermolecular Pd-catalysed coup-
lings to approach the targets [172]. The 4-Br in 66 was intro-
duced by electrophilic bromination of 4-nitroisoquinolinone 
20. Reduction furnished 4-bromo-5-AIQ 67. Neither 66 nor 
67 was an effective coupling partner, so the polar lactam was 
masked as the 1-methoxyisoquinoline 68, a strategy also 
used [92] for the couplings at the 3-position. Halogen-Li 
exchange and quench with iodomethane gave 69 (R = Me) in 
poor yield but Pd-catalysed Stille and Suzuki couplings eff-
iciently provided 69 (R = Me, Ar). Buchwald-Hartwig coup-
ling was also achieved. Demethylation and reduction led to 
the targets 65 (R = Me) and 71 (R = Ar). A shorter route via 
the 1-benzyloxy-4-bromo-intermediate 72 was also reported 
[172]. This route facilitated coupling to sterically crowded 
boronic acids, including preparation of analogue 73 (R = 
phenanthren-9-yl). Reduction of the nitro group and unmask-
ing the lactam were achieved simultaneously. The 4-substit-
uted-5-AIQs were evaluated biochemically, with most show-
ing inhibition of both PARP-1 and PARP-2 in the low M 
range. 
2.6.5. 6-Substituted analogue of 5-AIQ 
6-Methyl-5-AIQ 75 has been used as an intermediate in 
the assembly of a series of selective inhibitors of the mutant 
B-Raf, which contain aminoisoquinoline units [173]. Hydro-
lysis of the imino-chloride unit of 74, followed by reduction, 
Scheme 5. Structures of reported C-substituted analogues of 5-AIQ and associated chemistry. Reagents: i, NH3, MeOCH2CH2OH,  
[82,170]; ii, SnCl2 [170,171]; iii, H2, Pd/C [90,92,172]; iv, HBr, AcOH [92]; v, Pd(PPh3)4, Et3N, Bu4NCl, DMF,  [90]; vi, (COCl)2, DMF, 
(CH2Cl)2 [171]; vii, NaOMe [171]; viii, BuLi, THF, MeI, -78C [171]; ix, SnMe4, Pd2(dba)3, SPhos, PhMe,  [171]; x, ArB(OH)2, 
Pd2(dba)3, SPhos, PhMe,  [171]; xi, aq. HBr [171]; xiii, NaOBn [171]; xiii, aq. HCl, THF,  [172]; xiv, NaNO2, aq. HCl, KI [172]. 
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provided 75. A Sandmeyer reaction then introduced the 5-
iodine in 76 for later coupling reactions. 
3. CONCLUSIONS 
5-AIQ 1 is a development of the first “gold-standard” in-
hibitor of PARP-1, 3-AB 6, in which the critical amide is 
constrained to be coplanar with the benzene ring by incorp-
oration into a lactam ring. This coplanarity brings increased 
potency against PARP-1 but the retention of the primary 
arylamine (5-NH2 in 1) maintains the excellent physico-
chemical properties, especially the water-solubility as the 
hydrochloride salt. Efficient synthetic routes to 1 have been 
devised, making the agent readily accessible and available 
through commercial suppliers. 
5-AIQ is moderately potent against its original target 
enzyme, PARP-1, with IC50 = ca. 300 nM, depending on the 
nature of the assay. There is no selectivity for this isoform, 
however, with similar potency demonstrated for inhibition of 
PARP-2. The agent binds less well to the tankyrases (PARP-
5a and PARP-5b), with IC50 = ca. 10 M for inhibition of 
these isoforms. Off-target inhibition of non-PARP enzymes 
(MMP-2, diphtheria toxin) is weak. 
The excellent water-solubility and other properties of the 
hydrochloride salt of 1 lead to good cellular uptake, as dem-
onstrated in several functional studies and by measurement 
of apparent IC50 against poly(ADP-ribosyl)ation in cells. 
This PARP-1-inhibitory potency in cells gives 1 strong activ-
ity in models of oxidative damage to DNA. In these models, 
the dramatic depletion of substrate NAD+ by over-activated 
PARP-1 in cells is diminished or abolished by 1. These cell-
ular effects are translated into the remarkable potency of 1 in 
protecting against ischaemia-reperfusion injury in in-vivo 
models of a wide range of disease states. Of particular note is 
the significant protective activity of 1 at 30 g Kg-1 in a rat 
model of haemorrhagic shock [73]. Organs become isch-
aemic during transplantation and 1 protects effectively 
against damage and loss of function consequent to reper-
fusion in the recipient animal. 
Anti-inflammatory activity is also seen for 5-AIQ 1 in 
rodent models of arthritis and several other inflammatory 
disease states, including models of asthma and drug-induced 
lung inflammation and of damage to the spinal cord. This 
activity is largely due to down-regulation of the activity of 
NF-B, which is regulated by PARP-1. Inhibition of PARP-
1 activity with 1 therefore leads to down-regulation of 
expression of several effectors of inflammation, including 
ICAM-1, P-selectin and the matrix metalloproteinases.  
The expression of proteins involved in angiogenesis is 
also down-regulated by treatment with 5-AIQ 1, leading to 
inhibition of the angiogenesis process itself. Similarly, 
although 1 has only very modest direct anti-cancer activity in 
vivo, the down-regulation of the expression of MMP-2, 
MMP-9, P-selectin and ICAM-1, inter alia, leads to remark-
able anti-metastatic activity in a mouse model [15]. Some 
synergy has been noted between inhibition of PARP-1 with 1 
and inhibition of ART1 with meta-iodobenzylguanidine 
(MIBG), suggesting that these enzymes may be linked in 
some regulatory processes. 
3-Substituted analogues of 5-AIQ 1 have been investig-
ated thoroughly for their ability to inhibit the tankyrases 
(PARP-5a,b) [92]. 3-(para-Substituted-phenyl)-5-AIQs are 
particularly potent against these isoforms and show selectiv-
ity for the tankyrases over PARP-1 and PARP-2. 
Several inhibitors of PARP-1 (e.g. olaparib 7, rucaparib 8, 
veliparib 9 and niraparib 10) have entered clinical use or are 
in late stage clinical trial, largely with restricted indications 
(BRCA-mutant cancer). The very broad range of therapeutic 
activities demonstrated in vivo by the leading model agent 5-
AIQ 1, mediated by inhibition of PARP-1, points to much 
wider potential for therapeutic applications of PARP-1-
inhibitory drugs in a diverse human diseases. 
LIST OF ABBREVIATIONS 
3-AB, 3-aminobenzamide; 5-AIQ, 5-aminoisoquinolin-1-
one; Ac, acetyl; ADP, adenosine diphosphate; Akt, protein 
kinase B; ART1, ADP-ribosyl transferase-1; Ar, aromatic; 
BNCT, boron neutron capture therapy; BRCA, breast cancer 
type-1 susceptibility protein; BUN, blood urea nitrogen; 
DEAD, diethyl azodicarboxylate; DiBAL-H, diisobutylalum-
inium hydride;  DMF, dimethylformamide; DMFDMA, di-
methylformamide dimethylacetal / N-(dimethoxymethyl)di-
methylamine; DNA, deoxyribonucleic acid; EAE, experi-
mental autoimmune encephalomyelitis; Et, ethyl; FDA, Food 
and Drugs Administration; FGF, fibroblast growth factor; 
HATU, (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazol-
o[4,5-b]pyridinium 3-oxide hexafluorophosphate); HUVEC, 
human umbilical vein endothelial cell; IC50, concentration to 
inhibit activity by 50%; ICAM-1, intercellular adhesion mol-
ecule-1; logP, logarithm (base 10) of the octanol / water part-
ition coefficient; IB, inhibitory protein-B; Me, methyl; 
MMP, matrix metalloproteinase; mRNA, messenger ribo-
nucleic acid; MVP, major vault protein; NAD+, nicotinamide 
adenine dinucleotide; NF-B, nuclear factor-B; NuMA, 
nuclear mitotic apparatus protein; PARP, poly(ADP-ribose) 
polymerase; Pri, prop-2-yl; TEP-1, telomerase-associated 
protein-1; TGF-, transforming growth factor-; THF, tetra-
hydrofuran; TLR2, toll-like receptor 2; TNF-, tumour nec-
rosis factor ; VEGF-C, vascular endothelial growth factor-
C; vPARP, vault PARP; 
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